15/05/2026
⬅️
➡️
According to a report in The Lancet, the new name, polyendocrine metabolic ovarian syndrome, or PMOS, was chosen by a global coalition of patients, clinicians, and medical organizations to better reflect the condition’s wide-ranging hormonal and metabolic impacts.
The focus on ovarian cysts has led to delays in diagnoses and fragmented care, while the new name aims to improve how the condition is detected, treated, and explained, the researchers said.
Symptoms of PMOS include irregular or absent menstrual cycles, infertility, pregnancy complications, excess hair growth, acne, anxiety and depression, weight gain, obesity, diabetes and other disturbances in insulin, and cardiovascular disease.
Tap the link to learn more about the transition to the new terminology. https://mdsc.pe/4uNjedR